Pneumology Meets Oto-Rhino-Laryngology: A Discussion of Type 2 Inflammation in Airway Diseases
Present evidence from clinical trials and real-world experience to demonstrate the safety and efficacy of Dupilumab, a biologic targeting the key and central cytokines of Type 2 inflammation, in both upper and lower airway diseases.
.png/jcr:content/image%20(94).png)
.png0/jcr:content/1%20(2).png)
.png/jcr:content/2%20(3).png)
.png0/jcr:content/3%20(2).png)
MAT-BH-2300373/V1/JUNE 2023